Mutabilis will present at “Superbugs & Superdrugs”. 30-31 March 2020. London, UK.
Title of the talk : DISCOVERY OF DABOCINS, A NOVEL CLASS OF NON-BETA-LACTAM PBP INHIBITORS
- EBL-1463 is a DBO-based covalent inhibitor of Penicillin-Binding Proteins 1a, 2, 3
- It is stable to class A, B, C, D beta-lactamases, direct-acting and bactericidal against Enterobacterales
- Overview of MIC profiles and in vivo efficacy against highly resistant MBL-producing CRE
- Early PK/PD and human dose prediction
You must be logged in to post a comment.